

1 Co-immobilization of P450 BM3 and Glucose Dehydrogenase on different 2 supports for application as a self-sufficient oxidative biocatalyst

3

4 **Short title:** Co-immobilization of P450 BM3 and Glucose dehydrogenase on different supports

5

6 Jordi Solé¹, Gloria Caminal², Martin Schürmann³ and Gregorio Álvaro¹, Marina Guillén¹

7 ^aBioprocess Engineering and Applied Biocatalysis Group, Department of Chemical Biological

8 and Environmental Engineering, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.

9 ^bInstitut de Química Avançada de Catalunya (IQAC) CSIC, Jordi Girona 18-26, 08034, Barcelona,

10 Spain

11 ^cInnoSyn B.V., Urmonderbaan 22, 6167 RD Geleen, The Netherlands

12

13 **Corresponding author:**

14 Marina Guillén

15 Department of Chemical, Biological and Environmental Engineering, Universitat Autònoma de

16 Barcelona (UAB), 08193 Bellaterra, Catalonia, Spain

17 Telephone: +34 93 581 4793

18 Fax: +34 93 581 2013

19 marina.guillen@uab.cat

20

21

1

2

22Abstract

23BACKGROUND. The oxy-functionalization of non-activated carbon bonds by the bacterial
24cytochrome P450 BM3 from *Bacillus Megaterium*, presents a promising field in biosynthesis
25and it has gained much interest in recent decades. Nevertheless, the need for the expensive
26cofactor NADPH, together with low operational stability of the enzyme have made the
27implementation of this biocatalyst unfeasible in most cases for industry.

28RESULTS. P450 BM3 and glucose dehydrogenase (GDH), as a cofactor regeneration enzyme,
29were successfully co-immobilized obtaining a bi-functional self-sufficient oxidative biocatalyst.
30Firstly, a broad screening on 13 different supports was carried out. Afterwards, five selected
31agaroses with three different functionalities (epoxy, amine and aldehyde) were studied and
32their immobilization processes optimized. Finally, P450 BM3 and GDH, were co-immobilized on
33those supports showing the best performance for P450 BM3 immobilization: Epoxy-agarose
34(Epoxy-agarose-UAB) presenting 83% and 20% retained activities respectively; AMINO-agarose
35presenting 28% and 25% and Lentikats® with which both enzymes retained 100% of the initial
36activity. Furthermore, the re-utilization of the self-sufficient immobilized derivatives was tested
37in 5 repeated cycles.

38CONCLUSIONS. P450 BM3 and GDH have been successfully immobilized on three supports and
39their re-usability has been tested in a model reaction. It represents a step-forward for future
40P450 BM3 industrial implementations.

41

42

43

44

45Introduction

46Cytochromes P450 (CYPs) are versatile monooxygenases able to hydroxylate non-activated
47carbon bonds with the only requirement of molecular oxygen and an electron donor. CYPs are
48found as: (i) double domain proteins, presenting a heme-containing oxidative part and a
49FAD-/FMN-containing reductase; as (ii) triple domain enzymes with a third Ferredoxin subunit
50and (iii) as fusion proteins with just one enzymatic unit ¹. These enzymes have been in the
51focus of research in recent decades due to interest in their application as catalysts for the
52efficient production of fine chemicals, polymers, active pharmaceutical ingredients or
53nutritional supplements. They display a broad substrate range as well as the capability to
54catalyse a variety of oxidations including epoxidations, hydroxylation of aromatics, N-oxidation,
55deamination, dehalogenation and others ².

56P450 BM3 (EC 1.14.14.1) from *Bacillus megaterium* was discovered in 1986 and excels among
57CYPs because it presents the highest turnover numbers (17000 min⁻¹ for arachidonic acid) ^{3,4}. In
58contrast with eukaryotic CYPs, P450 BM3 is a self-sufficient soluble protein that contains both
59oxidative and reductase domains in the same polypeptide chain. Its natural substrates are
60medium to long chain fatty acids, however, as with other CYPs, P450 BM3 is a promiscuous
61enzyme. It accepts fatty amides and alcohols, hydroxylated fatty acids and ω-oxo fatty acids. It
62also displays, not only hydroxylating activity, but olefin epoxidation, ring expansion,
63heteroatom oxidation and dealkylation, and dehydrogenation across C-O, C-N and C-C bonds,
64as well as carbon-carbon bond formation and cleavage ⁵.

65There are some limitations in the large-scale application of P450 BM3 such as, low operational
66stability, a dependence on the expensive NADPH electron donor and low retained activity in
67organic media ⁶. Thus, there have been few cases where it has been attempt to be used
68industrially ^{7,8}. In order to tackle these bottlenecks, protein engineering, cofactor recycling

69systems, surface modifications, reaction media engineering or immobilization are the main
70strategies usually followed in biocatalytic processes.

71Regarding the low operational stability, immobilization has proven to be an efficient
72methodology for a broad type of oxidoreductases, not only for improving their stability but also
73for enhancing process metrics by biocatalyst recycling ^{9,10}. In addition, immobilization can
74confer operational advantages such as the possibility to operate in continuous mode, reduction
75of foam formation, increased stability in organic solvents or simplified product purification ^{11,12}.
76Immobilization of P450 BM3 has been pursued by other authors. For example, Maurer *et al.*
77tried to immobilize it on a variety of commercially available supports ¹³. They succeeded using
78the positively charged resins DEAE and SuperQ; and a Sol-Gel, but only the last one was found
79suitable for bioconversions. Axarli *et al.* immobilized a triple mutant onto Epoxy-sepharose,
80achieving retained activities of 81% and improved stabilities at 37°C ¹⁴. Weber *et al.* entrapped
81the heme-domain of the P450 BM3 into mesoporous molecular sieves (MCM-41 and SBA-15)
82and found a correlation between the activity observed from the derivative and pore diameter
83¹⁵. Furthermore, Zhao *et al.* immobilized a mutant on DEAE-650S, further entrapped into k-
84carrageenan together with catalase and zinc dust (Zn/Co(III)sep) which served as electron
85source. They could operate the reactor during 10 batch cycles with continued conversions
86above 80% ¹⁶. Other successful and more recent examples involved the fusion of the enzyme to
87linkers that enabled immobilization on solid surfaces ¹⁷⁻¹⁹. From all the works present in the
88literature, few are the cases where P450 BM3 has been successfully immobilized covalently for
89bioconversion purposes. Many of the above works focused on bio-sensing, in which low
90amounts of enzyme are required, or on the electrochemical study of the enzyme ²⁰. For large
91scale applications, the attachment of large quantities of the enzyme to solid matrices by
92covalent bonds is a robust method that often confers novel properties to the enzyme and it
93does not present leaching.

94With regard to electron donors, there have been attempts to substitute the expensive NADPH
 95co-substrate for less costly products, e.g. NADH or H₂O₂ by protein engineering ²¹⁻²³. In a
 96different way, electrochemical-driven catalysis has also proved successful to bypass the use of
 97NADPH. In various works, the immobilization of P450s on electrode surfaces, that served as
 98electrons sources, led to enzymatically catalysed product formation ²⁴⁻²⁷. Strategies for
 99regenerating the expensive NADPH has been also studied both in enzymatic and non-enzymatic
 100manners ²⁸⁻³⁰. The use of whole cell biocatalyst expressing P450 has been considered as a
 101suitable and much cheaper strategy by taking advantage of the cellular metabolism for NADPH
 102regeneration ^{31,32}. However, the use of whole cells entails several drawbacks such as secondary
 103undesired reactions or low reaction rates due to the substrate or product mass transfer
 104limitation. Among the different strategies for cofactor regeneration, the utilization of
 105secondary enzymes that make use of sacrificial substrates is one of the most attractive systems.
 106The use of enzymatic NADPH regeneration systems in P450-catalyzed reactions has been
 107reported by other authors. Different enzymes such as glucose dehydrogenase, formate
 108dehydrogenase or phosphite dehydrogenase proved to be efficient and suitable biocatalysts for
 109this purpose ^{13,33,34, 35}.

110In this work, a bi-functional self-sufficient oxidative biocatalyst is obtained by the successful co-
 111immobilization of P450 BM3 and a GDH from *Thermoplasma acidophilum* as cofactor-
 112regenerating enzyme (Figure 1). Firstly, P450 immobilization was analysed prior to the selection
 113of the best co-immobilization strategy since P450 is a less robust enzyme compared to GDH.
 114Thus, deeper understanding of P450 BM3 immobilization by two different enzyme-support
 115interactions (adsorption or covalent attachment) is presented. In this sense, different supports
 116presenting a broad range of features were tested to get insight in the optimal immobilization
 117procedure that should be followed. Finally, co-immobilization of P450 BM3 and GDH was
 118performed by applying the best methodologies resulting for the P450 BM3. The encapsulation

119in polyvinyl alcohol particles (Lentikats®) was also studied for the confinement of both P450
120BM3 and GDH as an alternative to adsorption and covalent attachment strategies.

121The resulting-self-sufficient biocatalysts were tested in terms of operational stability in the
122hydroxylation of sodium laureate as a model reaction for proof-of-concept.

123

124Experimental

125Materials and supports

126Nicotinamide adenine dinucleotide phosphate sodium salts in its oxidized and reduced form
127(NADP⁺ disodium salt and NADPH tetrasodium salt) was purchased from BONTAC
128Bioengineering (Shenzhen, Guandong, China). All the other reagents were purchased from
129Sigma Aldrich® (St. Louis, MO, USA) and were of analytical grade if not stated elsewhere.

130The supports used in the screening section were donated by Purolite® Life Sciences (Bala
131Cynwyd, PA, USA) and their features are summarized in Table 2.

132The Epoxy-agarose-SIGMA was purchased from Sigma-Aldrich®. According to the supplier's
133specifications it presented spherical shape, it had an activation degree of $\geq 20 \mu\text{mol/mL}$ and 12
134atoms spacer.

135Non-functionalized agarose (spherical beads \varnothing 50-150 μm) purchased from Agarose Bead
136Technologies® (ABT®, Madrid, Spain) was used for obtaining Epoxy-agarose-UAB by support
137functionalization carried out as described by Axarli *et al.* ¹⁴. The quantification of the epoxy
138groups present on the supports was done following the method described by Gupta ³⁶.

139Amino functionalized agarose (AMINO-agarose) presenting amino ethyl groups and aldehyde
140functionalized agarose (GLYOXYL-agarose) with an extent of labelling of 40-60 $\mu\text{mol/mL}$ both

141were also purchased from ABT[®]. All this information was always according to the supplier's
142specifications.

143Lentikats[®] polymer was purchased from GeniaLab[®] (Braunschweig, Germany) and its
144composition consists on a mixture of polyvinyl alcohol (10%), polyethylene glycol (6%) and
145demineralized water (84%).

146Recombinant expression of P450 BM3 and Glucose dehydrogenase in *E. coli*

147P450 BM3 (CYP102A1 from *Bacillus megaterium* BM3) was recombinantly produced in
148*Escherichia coli* in a 20 L scale batch fermentation employing an *E. coli* K12 derivative and a
149pBAD/myc-HisC based expression vector. Glucose Dehydrogenase (GDH) from *Thermoplasma*
150*acidophilum* (GDH-Tac) was co-expressed from the same vector in a poly-cistronic arrangement
151of the GDH gene downstream of the P450 BM3 gene. A 500 mL pre-culture were used to
152inoculate 20 kg main culture medium with 100 µg/mL neomycin. The pre-culture was prepared
153in standard Luria-Bertani (LB) medium supplemented with 100 µg/mL neomycin. The
154fermentation was performed using terrific broth (TB) medium with glycerol. 2.5 h after
155inoculation of the fermenter as inducer, pre-sterilized L-arabinose was added to the fermenter
156to final concentration 0.02% (w/v). 24 hours after inoculation of the fermenter, the cell
157material was harvested by centrifugation. Cell free extract was prepared by adding 2 weight
158equivalents of 100 mM potassium phosphate (KPi) buffer (pH 7.0) to 1 weight equivalent of *E.*
159*coli* wet cells and sonication of this cell suspension with an ultrasound probe for 20 min with
160cooling on ice and centrifugation to remove the cell-debris.

161Total protein and enzyme content

162The cell lysate was pre-clarified by centrifugation (3220 g for 15 min.) and analysed accounting
163for total protein content by means of Bradford Protein Assay Kit (Thermo Fisher Scientific,
164Waltham, USA) using bovine serum albumin as standard ³⁷.

165Enzyme content was assessed using the sodium dodecyl sulphate polyacrylamide gel
166electrophoresis (SDS-PAGE) (NuPage 12%, Invitrogen, USA) run in a Mini-PROTEAN II apparatus
167(BioRad, USA) following the protocol of Laemmli *et al.* ³⁸. Low range protein markers were used
168for molecular weight determination. Gels were stained using Coomassie G250 colloidal stain
169solution [34% (v/v) ethanol, 2% (v/v) H₃PO₄, 17% (w/v) NH₄SO₄ and 0.066% Coomassie G250]
170and the Image LABTM software (BioRad, USA) was used for image processing.

171Active P450 BM3 content determination

172P450 BM3 active form concentration was determined using the CO-differential spectra analysis
173described by Omura and Sato, using $\epsilon = 91 \text{ mM}^{-1} \text{ cm}^{-1}$ ^{39,40}.

174P450 BM3 activity measurement

175The activity of the P450 BM3 was measured spectrophotometrically ($\lambda=340 \text{ nm}$) following the
176consumption of NADPH ($\epsilon= 6.22 \text{ mM}^{-1} \text{ cm}^{-1}$, 200 μM), using sodium dodecanoate (sodium
177laurate) as substrate (1.3 mM dissolved in sodium phosphate buffer 50 mM pH=7.5). 25 μL of
178enzyme sample were added to the total volume of the assay (500 μL). The basal consumption
179of NADPH by unspecific enzymes present in the lysate or/and by P450 uncoupling in absence of
180substrate was determined by this same test but avoiding the addition of the substrate and
181adding buffer instead. This consumption rate, that represents about 2-3%, is subtracted from
182the measurement with sodium dodecanoate. One unit of activity (U) is defined as the enzyme
183required to convert 1 μmol of NADPH per minute at those given conditions (30°C and pH = 7.5).
184The absorbance was recorded using a spectrophotometer Cary 50 Bio UV-visible (Palo Alto,
185USA). The equipment allows temperature control and stirring. Plastic micro cuvettes BRAND®
186UV (Sigma Aldrich®) were used for soluble enzyme characterization and 3.5 mL quartz cuvettes
187HELLMA® 100-QS (Hellma Analytics, Müllheim, Germany) with magnetic stirring, were used for
188the immobilized derivatives (suspension). In the first case a total volume of 500 μL was reached
189while in the second it was 2 mL.

190 Glucose dehydrogenase activity measurement

191 GDH activity is measured spectrophotometrically ($\lambda=340$ nm) following the formation of
192 NADPH. Certain amount of sample ($1/20$ of the V_T) was added to a solution containing D-
193 Glucose (200 mM dissolved in sodium phosphate buffer 100 mM pH=8) and NADP^+ (400 μM).
194 The same procedure explained above was applied for measuring the non-GDH formation of
195 NADPH and the same consideration is taken to obtain the U_s . Moreover, it was checked that if
196 NADPH is used instead of NADP^+ , no consumption of cofactor by P450 is detected under the
197 test conditions. The absorbance was also recorded using the aforementioned equipment and
198 conditions.

199 Immobilization metrics

200 In every immobilization, a characterization was pursued in order to obtain the retained activity
201 (equation 1) and immobilization yield (equation 2). Supernatant and suspension activities were
202 analysed over time until a steady state was reached and in all cases the activity of a blank (no
203 support) was also monitored to ensure that the enzyme activity was not affected by protocol's
204 conditions. A 10% w/v relation between the support and the total volume was always
205 established and small amounts of enzyme were loaded (4-5 U of P450 BM3/g of support and 5-6
206 U of GDH/g of support) so that diffusional limitations were minimized.

$$207 \text{ Retained activity (\%)} = \frac{\text{Suspension activity} \left(\frac{U}{g} \right) - \text{Supernatant activity} \left(\frac{U}{g} \right)}{\text{Initial offered activity} \left(\frac{U}{g} \right)} \times 100$$

208 (Equation 1)

$$209 \text{ Immobilization yield (\%)} = \left(1 - \frac{\text{Supernatant activity} \left(\frac{U}{g} \right)}{\text{Initial offered activity} \left(\frac{U}{g} \right)} \right) \times 100 \quad (\text{Equation 2})$$

For the assessment of the loading capacity the supports were saturated with enzyme and the activity was calculated taking into account that diffusional limitations do not allow the actual visualization of the activity in the support (equation 3).

$$\text{Loading capacity} \left(\frac{U}{g} \right) = \left(\text{Offered initial activity} \left(\frac{U}{g} \right) - \text{Supernatant activity} \left(\frac{U}{g} \right) \right) \times \frac{\text{Retained activity} (\%)}{\text{Immobilization yield} (\%)}$$

(Equation 3)

Moreover, the amount of protein per gram of support was also calculated, analysing the initial protein content and subtracting from it, the concentration still remaining in the supernatant at the end of the process. In all cases protein concentration was determined by means of Bradford Protein Assay Kit, as already described.

Immobilization of P450 BM3 onto Purolite® resins

From Purolite®, a set of commercially available resins presenting a variety of matrices, pore sizes, linker lengths, and functional groups (Table 2) were tested for the immobilization of P450 BM3. The conditions in which immobilizations were carried out in each case were those specified by the supplier's protocols. In all cases, the relation of 10% w/v between support and total volume was maintained. The immobilizations were done at 25°C and mild agitation. The incubation times ranged from 0.5 to 5 hours depending on the speed at which the enzymes were attached. The epoxy containing methacrylates (ECR8204F, ECR8215F and ECR8285) were used in 50 mM sodium phosphate buffer pH 8 containing 0.5 M NaCl. The amino functionalized resins (ECR8309F, ECR8315F, ECR8409F and ECR8415F) were mixed with the enzyme in 50 mM sodium phosphate buffer pH 6. The supports made of a mixture of styrene and methacrylate (ECR1061M and ECR1030M) were utilized in 50mM sodium phosphate buffer pH 7.5; finally, immobilizations using the epoxy agaroses (Praesto 45, 65 and 90) were performed in 1 M potassium phosphate buffer pH 8.

Immobilization of P450 BM3 onto Epoxy-agarose-SIGMA and Epoxy-agarose-UAB supports

234For the other epoxy-agaroses (Epoxy-agarose-SIGMA and Epoxy-agarose-UAB), the enzyme was
235dissolved in 1 M (pH 8) potassium phosphate buffer, mixed with the resin (10% w/v) and left at
23625°C with mild agitation. The Epoxy-agarose-UAB was incubated for 4 hours and Epoxy-
237agarose-SIGMA was incubated for 0.5 h. At the end of the process, in order to eliminate the
238unreacted epoxy groups, the samples were incubated with 0.2 M β -mercaptoethanol for at
239least 2 h at 25°C.

240Immobilization of P450 BM3 onto GLYOXYL-agarose support

241For the immobilization using GLYOXYL-agarose different pH's were tested (6.5 – 8.5) using 50
242mM sodium phosphate buffers. The immobilizations lasted 6 hours and were done at 25°C and
243mild agitation. For the reduction of the Schiff base, two different reducing agents were studied:
244sodium borohydride (1 mg/mL) added at the end of the immobilization and sodium
245cyanoborohydride (0.05 mg/mL for characterization and 0.4 mg/mL for high loads of enzyme)
246added at the beginning of the immobilization.

247Immobilization of P450 BM3 onto AMINO-agarose support

248For AMINO-agarose, 50mM sodium phosphate buffer (pH 6) was used to dissolve the enzyme
249and mix it with the support. Coming up next, the enzyme was left to ionically adsorb onto the
250support for 0.5 h-1 h. After that, a 200mM stock solution of N-(3-Dimethylaminopropyl)-N'-
251ethylcarbodiimide (EDC) was prepared dissolving it in 50 mM phosphate buffer and adjusting to
252pH 6 with HCl. It was then added at different concentrations and incubated for 30 min. to
253activate the carboxylic groups and promote the covalent binding. The concentration of EDC was
254optimized in the characterization phase (1, 2, 3, 4, 5, 10, 15, 20 mM) and also when using high
255loads of enzyme (3, 6, 12, 30, 60 mM). Finally, 0.5 M NaCl was introduced to desorb all the
256protein attached non-covalently. The immobilization was carried out at 25°C and mild agitation.

257Co-immobilization of P450 BM3 and GDH in AMINO-agarose and Epoxy-agarose-UAB

258The conditions in which immobilizations were carried out were exactly the same as previously
259described for P450 BM3 for AMINO-agarose and Epoxy-agarose-UAB. The activity of the GDH
260present in the lysate was also monitored in this stage together with the P450 BM3. Retained
261activities and immobilization yields were obtained for GDH and P450 BM3.

262**Co-Immobilization of P450 and GDH into polyvinyl alcohol lenses (Lentikats®)**

263Co-immobilization of GDH and P450 BM3 by entrapment was carried out using an organic
264polymer commercialized as Lentikats®. The solid mixture was heated up to 95°C until it turned
265into a transparent liquid. Then it was cooled down to 40°C and 8 mL of the polymer were mixed
266with 2 mL of a suspension containing the desired amount of biocatalyst. Afterwards the
267mixture was poured on a petri dish and the lenses were printed using the LentiPrinter®. The
268resulting plates were left to dry at 25°C for 1 h until they lost 80% of its weight approximately.
269Once printed, the support adopted a lentil-like shape of 1-2 mm diameter and 200-300 µm
270wide where the proteins were entrapped inside.

271**Re-usability of the biocatalyst for the hydroxylation of sodium laureate**

272The utilization of the immobilized enzymes in repeated reaction cycles were studied following
273the consumption of sodium laurate. The reactor ($V_T=5$ mL) contained 1.53 mM sodium laurate,
2740.2 mM NADP⁺ and 12.5 mM D-glucose. All dissolved in 50 mM sodium phosphate buffer pH
2757.5. The enzyme added was the minimum necessary to convert at least 90% of the initial
276substrate in 1 hour. The reactors used were purchased from MultiSynTech (Witten, Germany)
277and consisted of 10mL plastic vessels with a porous plate at the bottom. It allowed the
278extraction of the whole reactor liquid content by filtering with this same porous plate without
279losing any fraction of the immobilized derivative. The reaction took place at 25°C and 1000 rpm
280using a Multi-Therm H5000-HC-E thermo-shaker (Benchmark Scientific Inc., Sayreville, NJ,
281USA). After each cycle, the immobilized enzymes were washed twice with sodium phosphate

282buffer 50 mM pH 7.5 then new reaction medium was added and substrate conversion was
283quantified. Experiments were carried out in duplicate.

284GC-FID analysis of sodium laurate

285Samples containing sodium laurate and its products were analysed using a 7890A gas
286chromatograph (Agilent Technologies, USA) equipped with a HP-INNOWAX 19095N-123 column
287(30 m, 0.53 mm, 1 μ m, Agilent Technologies). Reaction samples were filtered (\varnothing 0.22 μ m) and
28850 μ L of hexanoic acid (2.8 mg/mL), that served as internal standard, were added to 300 μ L of
289sample. The column temperature started at 150 $^{\circ}$ C, increased to 240 $^{\circ}$ C at 24 $^{\circ}$ C/min. and it was
290held at final temperature for 11 minutes. The injector temperature was kept at 300 $^{\circ}$ C; for the
291flame ionization detector, the temperature was 320 $^{\circ}$ C. Helium was used as a carrier gas at a
292flow rate of 8 mL/min. All analyses were carried out in duplicate.

293

294Results and discussion

295Characterization of the *E. coli* lysate containing P450 BM3 and GDH

296As already mentioned, P450s are enzymes that require a cofactor to perform the redox
297reactions they catalyse. One of the strategies widely used for overcoming the disadvantages of
298co-factor dependency is the use of an enzyme-coupled reaction for the regeneration of the
299expensive NADPH. In this work, GDH (EC 1.1.1.47) from the archaea *Thermoplasma*
300*acidophilum* was used as NADPH-recycling enzyme using glucose as sacrificial substrate (Figure
3011). This robust and stable tetrameric protein is reported to be an efficient enzyme for NADPH
302regeneration^{34,35,41}.

303In the present work, GDH was co-expressed with P450 BM3 in *E. coli* and both enzymes were
304present in the cell lysates utilized.

The characterization of the lysate was performed regarding protein content, enzyme content (SDS-PAGE, Figure 2), activity and P450 BM3 active form concentration and the results are shown in Table 1.

The P450 BM3 was expressed at a higher level than the GDH, however, under the conditions in which the activity tests were performed, GDH gave higher specific activity. Table 1, also shows the correlation between activity units (Us) and concentration (nmols) of active enzyme; for the P450 BM3 case, 2.85 U/nmol.

Screening of supports for the immobilization of P450 BM3 – Purolite®

The main objective of the present work was to obtain a bi-functional self-sufficient oxidative biocatalyst by co-immobilization of P450 BM3 and GDH. To accomplish this, supports and immobilization conditions that were found to be most suitable for the P450 BM3 enzyme were prioritised, since cytochrome is the key enzyme performing the target reaction and it has been described as an unfavourable enzyme for immobilizing. GDH, on the contrary, has been described as a robust and more stable enzyme so difficulties in its immobilisation were not anticipated⁴¹. In fact, successful immobilization of GDH on different kinds of support has been reported by several authors⁴². The results obtained for P450 BM3 immobilization, the materials tested and its features are summarized in Table 2. The supports purchased in the screening kits encompass a range of different particle sizes (45 µm to 710 µm), matrices (methacrylate, styrene and agarose), functional groups (amino, epoxy and aldehyde), enzyme-support interaction (covalent binding or hydrophobic adsorption) and linker lengths (2 to 18 carbon atoms). All of these properties have been identified as critical for successful enzyme immobilization¹².

As shown in Table 2, the immobilization yields obtained were higher than 90% in all cases, except for the supports that interact with the enzyme by hydrophobic adsorption: ECR1061M and ECR1030M. In both cases the immobilization yields only reached 21±6% and 33±1%

330respectively. On the other hand, no retained activities or very low values (<20%) were observed
331in all tested supports, except for Praesto 45, 65 and 90, all epoxy-agarose supports (Figure 3A).
332According to the titration performed, Praesto 45, 65 and 90 contained an epoxide
333concentration of 9, 6 and 8 μmol per gram of support respectively and resulted in retained
334activities of 60-68% after 4h incubation. The maximum loading capacities of these epoxy-
335agarose resins ranged from 18 to 20 U/g and 7 to 8 mg protein/g of support. The
336immobilization profiles were very similar among the three supports and they did not show any
337significant correlation with the particle size or the initial epoxide concentration (Figure 3A).

338Regarding the methacrylate and styrene matrices, even though different ionic strengths and pH
339values were assessed, none of the tested supports showed retained activities above 20%. P450
340BM3 had adhered to the matrices in most cases, but did not remain active. Two methacrylate-
341based materials harbouring amino groups on six carbon chain linkers (ECR8409F and the
342ECR8415F) gave retained activities of $24\pm4\%$ and $22\pm3\%$ respectively when the enzyme was
343adsorbed onto the resins solely by ionic interactions, however once carbodiimide was added,
344to promote covalent bond formation, the activity was reduced to $6\pm3\%$ and $18\pm1\%$
345respectively. Furthermore, following the supplier's protocol, the four amino methacrylate
346based supports were further functionalized with glutaraldehyde prior to enzyme binding, but
347none resulted in successful immobilization either.

348It should be also mentioned that methacrylic matrices with the same functional groups than
349the epoxy-agarose support (ECR8204F, ECR8215F and ECR8285) did not lead to actively
350immobilized enzyme, as can be seen by the low retained activities obtained (0%, $2\pm1\%$ and
351 $13\pm2\%$ respectively). These results could indicate that for P450 immobilization the hydrophilicity
352of the matrix is a key factor. The higher hydrophobicity of the methacrylate/styrene matrices,
353together with the flexible nature of the enzyme and the presence of two active sites, are
354probably the causes behind the deactivation of the biocatalyst ⁴³. This hypothesis would be also

355in accordance with the low immobilization yields and retained activities obtained with the
356styrene matrices (ECR1061M and ECR1030M). The immobilization mechanism of these
357matrices is also based on hydrophobic adsorption and both the immobilisation yield and
358retained activity are low. Other authors have also reported unsuccessful attempts to
359immobilize P450s by hydrophobic adsorption. Maurer *et al.* attempted to immobilize the P450
360BM3 on hydrophobic supports such as EP100, MP1000, phenylsepharose, octylsepharose and
361nutysepharose but none of them presented final retained activity ¹³.

362Taking into account the obtained results in the screening which showed a strong effect of the
363hydrophilicity of the matrix on P450 immobilization, agarose was chosen to perform further
364studies.

365Immobilization of P450 BM3 onto different functionalized agaroses

366In addition to the epoxy resins already tested (Praesto 45, 65 and 90), two other agarose
367matrices with free epoxy groups and different epoxide concentrations were studied: a
368commercial lyophilized epoxy-agarose resin from Sigma-Aldrich® (Epoxy-agarose-SIGMA) and
369an in-house functionalized agarose resin (Epoxy-agarose-UAB) prepared as shown in the
370experimental section. In addition, an agarose based matrices containing aldehyde (GLYOXYL-
371agarose) and primary amine (AMINO-agarose) functional groups were tested.

372The Epoxy-agarose-SIGMA resin, according to the titration performed, contained an epoxide
373concentration of 110 ± 7 $\mu\text{mol/g}$ of support and gave an immobilization yield greater than 95%
374after 0.5 h (Figure 3B). However, a rapid decrease in activity of the suspended biocatalyst was
375noted during the immobilization procedure, indicating a strong deactivation of the enzyme
376after immobilization. Thus, after just half an hour, low retained activities ($35 \pm 8\%$) were
377observed from this support. These results could indicate that the utilization of an epoxy-
378agarose with high epoxide concentration, such as the Epoxy-agarose-SIGMA, results in a
379progressive loss of activity over time due to the multipoint attachment of the enzyme to the

support⁴⁴. The explanation can be found in the reactivity of the epoxy groups which differs over time: firstly, reacting with the amines present on the surface of the enzyme and secondly reacting with the carboxyl and thiol groups⁴⁵. At the end, if the incubation time is long enough, the protein can be attached by too many points and lose its whole catalytic activity. This issue can be stopped adding a blocking agent that removes the unreacted epoxy groups once the protein is immobilized. In Figure 3B, β -mercaptoethanol (0.2 M final concentration) was added after 0.5 h and the suspension was incubated for 3.5 h at 25°C. No significant loss of activity was observed during this period which validates the hypothesis of the multipoint attachment as the main reason for enzyme deactivation. However, due to its elevated cost (118 €/g) and low retained activities, compared to the Praesto supports, the Epoxy-agarose-SIGMA was discarded from further studies.

On the other hand, the Epoxy-agarose-UAB displayed an epoxide concentration of 30 ± 3 $\mu\text{mol/g}$ of support and gave more than a 95% immobilization yield and $83 \pm 8\%$ retained activity after 0.5 h (Figure 3C), with a maximum loading capacity of 30 ± 2 U/g of support (7.5 ± 0.8 mg protein/g of support). A decrease in retained activity can be also seen, reaching $50 \pm 5\%$ after 4h of incubation probably due to the excessive number of covalent bindings. In this case, as well as for Praesto supports (Figure 3A), the agarose contains a lower epoxide concentration compared to Epoxy-agarose-SIGMA. Therefore, the activity loss due to the multipoint attachment is lower for the Epoxy-agarose-UAB or even negligible for the Praesto compared to the Epoxy-agarose-SIGMA. Thus, when choosing the right support, a consensus should be found. Higher epoxide concentration may imply higher loading capacity as is seen when comparing Praesto (18 to 20 U/g of support) and Epoxy-agarose-UAB (30 ± 2 U/g of support); however, at the same time, higher epoxide concentration entails higher deactivation of the enzyme over time as it is the case comparing all three epoxy-agaroses: Praesto (32-40% activity lost), Epoxy-agarose-SIGMA (75% activity lost) and Epoxy-agarose-UAB (50% activity lost). In this sense, due to the loading capacity, the high retained activities reached and the low cost

406(2.5 €/g), the Epoxy-agarose-UAB was considered the best candidate for the immobilization of
407P450 BM3 among epoxy-agaroses. This study represents a deeper insight into the work of
408Axarli *et al.*¹⁴ in the understanding of the immobilization of P450 BM3 on epoxy-agaroses and
409sets the bases for an optimal process.

410As mentioned before, other agarose-based supports with different functional groups were also
411tested such as GLYOXYL-agarose and AMINO-agarose. The GLYOXYL-agarose (aldehyde
412activated) immobilization must be pursued in alkali media⁴⁶, however, P450 BM3 is not stable
413above pH 8.5 (data not shown). After screening a range of immobilization pH's (6.5 – 8.5), 7.5
414was the best performing one resulting in 50±2% retained activity after 6 h incubation. For the
415reduction of the Schiff base formed between the aldehyde of the resin and the amine of the
416enzyme, two reducing agents were tested: i) sodium borohydride (1 mg/mL) which is added at
417the end of the incubation and ii) sodium cyanoborohydride (0.05 mg/mL) which has slower
418kinetics and can be added at the beginning of the immobilization. Sodium borohydride resulted
419in a complete deactivation of the enzyme whilst the sodium cyanoborohydride strategy
420resulted in 36±0.1% of retained activity. Thus, sodium cyanoborohydride was selected as the
421most suitable reducing agent. Regarding the studies on maximum loading capacity, the values
422previously obtained in the characterization (36±0.1% retained activity) at low enzyme loadings
423were not extrapolated and a major inactivation occurred. This support has proved suitable for
424the immobilization of P450 BM3, nevertheless, since the covalent immobilization using high
425loading was not successful, it was discarded from further studies.

426Regarding AMINO-agarose, as for the other tested supports functionalized by amino groups
427(i.e. ECR8309F, ECR8315F, ECR8409F and ECR8415F) the immobilization is based on a three-
428stage process. In the first stage, the enzyme is adsorbed onto the support surface by ionic
429interaction of the amino groups of the support and the carboxyl groups of the enzyme, thus an
430ionic adsorption occurs. In the second stage, carbodiimide is added to the medium aiming to

activate the carboxyl groups present on the enzyme making covalent bonding possible. Solutions with high ionic strength such as sodium chloride (0.5 M) can be finally added to desorb all the protein attached non-covalently (third stage). Ionic adsorption on AMINO-agarose was performed at pH 6 and gave a $58 \pm 6\%$ retained activity (Figure 3D phase I). This value was 2.4-2.6 fold higher than the retained activities obtained during the ionic adsorption for the methacrylate based materials ECR8409F and ECR8415F harbouring the same functional group ($24 \pm 4\%$ and $22 \pm 3\%$), as previously discussed. The maximum loading capacity achieved was 112 ± 2 U/g of support (50 ± 4 mg protein/g of support) which represents the highest value among all the resins tested. Covalent binding of the amine and the carboxyl groups was carried out by adding EDC following ionic adsorption phase (Figure 3D phase II). Since carbodiimide can lead to enzyme deactivation, different concentrations and incubation times were studied to determine the optimal conditions for the covalent binding phase. These studies showed optimal values of 3 mM EDC and 30 min reaction time respectively. Following covalent attachment, the biocatalyst was incubated with 0.5 M NaCl for 2 h (Figure 3D, phase III) in order to increase the ionic strength of the media and release all the protein not adhered covalently. $28 \pm 1\%$ of the initial activity offered was covalently bound to the agarose, which represents 30% less activity than the value obtained for the ionic adsorption phase (Figure 3D, phase I). On the other hand, compared to the methacrylate-based supports, the retained activity was 4.7-fold and 1.6-fold higher than the obtained with ECR8409F and ECR8415F respectively. Regarding the maximum load, 53 ± 2 U/g of resin was reached (47 ± 3 mg protein/g of support), representing a 52% decrease in immobilized activity compared to the obtained by ionic adsorption, likely due to enzyme deactivation caused by the carbodiimide. When testing for the maximum loading capacity the concentration of EDC was further optimized since more enzyme was added (Figure 4). It resulted in an optimal concentration between 6 and 12 mM. This second value was chosen due to the higher immobilization yield that it entailed. This support represents a step forward in comparison with the other tested agaroses and it is the

457first work reporting a successful covalent immobilization of P450 BM3 in an amino-based
458matrix.

459Other authors have worked with P450s and agarose based matrices before. In 1988 *King et. al.*
460obtained 100% immobilization yield and 66% retained activity using a cyanogen bormide-
461sepharose 4BCL and a P450 from *Saccharomyces cerevisiae*. Another example is the
462aforementioned case of Axarli *et al.* that immobilized the P450 BM3 on epoxy-agarose and
463obtained 81% retained activity¹⁴.

464Co-immobilization of P450 BM3 and Glucose dehydrogenase

465As it has been already mentioned, for co-immobilization of both GDH and P450 BM3, it was
466considered to prioritize the supports and immobilization conditions that were found to be
467suitable for P450 BM3, i.e. Epoxy-agarose-UAB and AMINO-agarose.

468The immobilization of GDH using Epoxy-agarose-UAB resulted in poor affinity of the protein for
469the support with immobilization yields below 20%. However, of the enzyme that did adhere, a
470slight over-activation was observed compared to the same quantity of free enzyme. At the end
471of the incubation (4 h), retained activity of $20 \pm 5\%$ and a maximum loading capacity of 3 ± 0.1
472U/g of support were achieved. Since the conditions were exactly the same as reported above
473for P450 BM3, the activity for the cytochrome was comparable and resulted in $50 \pm 5\%$ retained
474activity and 30 ± 2 U/g (7.5 ± 0.8 mg protein/g of support).

475With AMINO-agarose, GDH presented high affinity for the support and it also showed an over-
476activation effect when adhered to the matrix. It had better tolerance to the presence of EDC
477compared with P450 BM3, with 10 mM being the optimal concentration for this enzyme
478($57 \pm 2\%$ retained activity) in the characterization phase. Co-immobilization of both enzymes,
479initially using a low carbodiimide concentration of 3mM, resulted in a $25 \pm 4\%$ retained activity
480for GDH and $28 \pm 1\%$ for P450 BM3. Using a higher loading of EDC (12 mM) resulted in a loading

481capacity of 18 ± 1 U/g of support for GDH and 53 ± 2 U/g of support for P450 BM3. In summary,
482a self-sufficient oxidative biocatalyst was obtained.

483There are several examples in the literature of the immobilization of GDH ⁴². Regarding the
484immobilization on agarose based matrices, Anwar *et al.* immobilized a baker's yeast GDH on
485cyanogen bromide-sepharose obtaining a retained activity of 3% ⁴⁷. Persson *et al.* purified a
486GDH from *Bacillus subtilis* by immobilizing it on thiopropyl-sepharose and recovered up to 65%
487of the initial activity ⁴⁸. However, as far as the authors know, this is the first time that GDH has
488been covalently co-immobilized with P450 BM3.

489Co-immobilization of P450 BM3 and GDH into polyvinyl alcohol particles - Entrapment

490Finally, as an alternative to immobilization by adsorption or by covalent attachment, an
491entrapment strategy was also investigated for co-immobilization. Both P450 BM3 and GDH
492were successfully embedded into Lentikats[®] (polyvinyl matrix) as described in the experimental
493section. The analysis undertaken, showed maximum retained activities of $100 \pm 0.1\%$ for both
494P450 BM3 and GDH.

495In the sense of the loading capacity employed, the activity and concentration of protein in the
496polymer was 1.8 ± 0.2 U/g of P450 BM3, 0.8 ± 0.1 U/g of GDH and 1.1 ± 0.1 mg protein/g of
497support respectively. It was not further increased due to operational issues. The capacity is
498limited by an aggregation effect observed when charging high concentrations of lysate with
499which the lenses form a compact mass that cannot be used in our reactions. This entails a
500serious drawback when looking to industrial feasibility because the enzyme should be
501previously purified or the specific activity of the support would remain too low ³¹. However,
502since the immobilization had been successful, albeit with low enzyme loading, and it is the first
503work that reports a successful entrapment of both P450 BM3 and GDH in Lentikats[®], it was
504decided to continue working with this immobilized derivative.

505Reusability of the biocatalyst using sodium laurate as substrate

From all the supports tested, AMINO-agarose, Epoxy-agarose-UAB and Lentikats® were considered good candidates to be potential carriers in bio-catalysis applications. It is well-known that uncoupling effects on P450s produce reactive oxygen species that inactivate the enzyme (uncoupling)⁴⁹. This handicap is less relevant when working with native substrates such as sodium laurate and so this substrate was used as a model for studying the reusability of the self-sufficient biocatalyst. Firstly, the coupling efficiency of P450 towards this substrate was determined and then reusability studies were performed using the self-sufficient P450/GDH biocatalysts obtained with the aforementioned carriers.

Reactions using sodium laurate (1.3 mM) and NADPH (0.2 mM) were performed, monitoring and comparing substrates consumption by means of GC-FID. A coupling efficiency of $90.4 \pm 8.3\%$ was observed, which means that, 90.4% of the NADPH consumed was employed for sodium laurate hydroxylation, with the remainder directed towards uncoupled reactions. This substrate was considered adequate to assess the operational stability of the enzymes in repeated reaction cycles.

Total turnover number (mols of substrate consumed/mols of P450 BM3) (TTN) was chosen as the metric to evaluate the yield of the self-sufficient biocatalyst in comparison with the soluble lysate. To assess it, the immobilized P450 BM3/GDH (Epoxy-agarose-UAB, AMINO-agarose and Lentikats®) biocatalysts were tested in sodium laurate reaction cycles of 1 hour each utilizing glucose as the sacrificial substrate and the cofactor in its oxidized form (NADP^+) thus forcing the cofactor regeneration to start before the P450-catalyzed reaction. Moreover, NADP^+ starting concentration was 6.5-fold lower than the sodium laurate. The amount of P450 BM3 required to convert > 90% of sodium laurate in 1 hour was found to be 0.18-0.2 U/mL (0.063-0.07 nmols/mL). GDH on the other hand, was always ensured to be present in excess so that it did not limit the hydroxylation reaction. The conversions obtained in each cycle for the immobilized systems are presented in Figure 5. The TTN for the soluble reaction was

53121,500±290 mols of sodium laurate consumed/mol of P450 BM3 in 1 hour of reaction. The
532immobilized derivatives allowed the re-utilisation of the self-sufficient biocatalyst boosting the
533TTN by 2.31-fold for the Epoxy-agarose-UAB, 2.98-fold for AMINO-agarose and 2.3-fold for the
534enzymes immobilized into Lentikats®. As shown in Figure 5, the conversion dropped in an
535exponential manner for epoxy-agarose (Figure 5A). On the contrary, with AMINO-agarose and
536Lentikats® the decay was more linear (Figure 5B and 5C). At the end, all three derivatives could
537be re-used successfully, thus demonstrating a significant operational stability.

538Some examples can be found in the literature about the reusability of P450s. Lee *et al.*
539immobilized a phasin fused P450 BM3 and re-used it 4 times with no loss of activity ¹⁷. Zhao *et*
540*al.* were able to use a P450 BM3 mutein together with catalase in 10 batch cycles with
541conversions up to 80% ¹⁶. Regarding GDH, different studies of re-usability have been reported.
542A recent example, Petrovicová *et al.* co-immobilized a ketoreductase and a GDH from *Bacillus*
543*megaterium* in polyvinyl alcohol particles and were able to use the derivate 18 times with
544minimal loss of activity ⁵⁰.

545

546Conclusions

547P450 BM3 has gained much interest in recent years in biocatalysis for its oxy-functionalization
548characteristics, although, the implementation of this enzyme in industrial processes has lacked
549optimal metrics. Operational stability as well as its requirement of NADPH in stoichiometric
550amounts have been identified as the main bottlenecks. Aiming to overcome these two main
551drawbacks, P450 BM3 and GDH have been co-immobilized in the present work to obtain a
552robust bi-functional self-sufficient biocatalyst.

553P450 BM3 and GDH were covalently co-immobilized on epoxy-functionalized agarose and
554amino-functionalized agarose. Both enzymes were also successfully co-immobilized by

555 entrapment in a polyvinyl alcohol/polyethylen-glycol matrix named Lentikats®. From the five
556 epoxy-agaroses tested, the optimal support (Epoxy-agarose-UAB) presented an epoxide
557 concentration of 30 ± 3 $\mu\text{mol/g}$ of support and retained activities of $83 \pm 8\%$ for P450 BM3 and
558 $20 \pm 5\%$ for GDH. On the other hand, AMINO-agarose showed retained activities of $28 \pm 1\%$ for
559 P450 and $25 \pm 4\%$ for GDH. Finally, the entrapment of both enzymes in Lentikats® lead to P450
560 BM3 and GDH co-immobilization maintaining 100% of the activity initially loaded.

561 P450 BM3 was also immobilized on aldehyde-functionalized agarose and presented $36 \pm 0.1\%$
562 retained activity. However, this support did not allow high enzyme loads required for reaction
563 testing, thus making this support unattractive for further studies.

564 The operational stability of the obtained bi-functional self-sufficient biocatalysts (Epoxy-
565 agarose-UAB, AMINO-agarose and Lentikats®) was analysed in terms of re-usability for sodium
566 laureate oxidation. All three derivatives showed successful reuse in 5 cycles, entailing an
567 increment in the TTN of 2.31-fold the Epoxy-agarose-UAB, 2.98-fold the AMINO-agarose and
568 2.3-fold the Lentikats® compared to the soluble enzymes.

569 The P450 BM3 wild type served as a model in the immobilization studies in this work. On the
570 other hand, mutated P450 BM3s, usually required for oxidative reactions of non-natural
571 substrates which entail high uncoupling effects, can follow the exact same principles reported
572 here since the surface of the enzyme is usually unaffected^{1,5,6,51}. In this sense, immobilization
573 can be an added value to the process, for these new enzymes, due to the many advantages
574 that it confers.

575

576 Acknowledgements

577 The research for this work has received funding from the European Union project ROBOX
578 (grant agreement n° 635734) under EU's Horizon 2020 Programme Research and Innovation

579actions H2020-LEIT BIO-2014-1. This document reflects only the author's view and the Agency
580is not responsible for any use that may be made of the information it contains. The
581Department of Chemical, Biological and Environmental Engineering of Universitat Autònoma
582de Barcelona constitutes the Biochemical Engineering Unit of the Reference Network in
583Biotechnology and the research group 2017 SGR 1462, Generalitat de Catalunya. Authors also
584thank COST Action CM 1303-Systems Biocatalysis for financial support and Purolite Life
585Sciences® for the supports given. Jordi Solé acknowledges also UAB for funding his Ph.D. grant.

586

587References

- 588 1. Urlacher, V. B. & Girhard, M. Cytochrome P450 monooxygenases: An update on
589 perspectives for synthetic application. *Trends Biotechnol.* **30**, 26–36 (2012).
5902. Guengerich, F. P. Common and Uncommon Cytochrome P450 Reactions Related to
591 Metabolism and Chemical Toxicity. *Chem. Res. Toxicol.* **14**, 611–650 (2001).
5923. Narhi, L. O. & Fulco, A. J. Characterization of a catalytically self-sufficient 119,000-dalton
593 cytochrome P-450 monooxygenase induced by barbiturates in *Bacillus megaterium*. *J.*
594 *Biol. Chem.* **261**, 7160–7169 (1986).
5954. Warman, A. J. *et al.* Flavocytochrome P450 BM3: an update on structure and
596 mechanism of a biotechnologically important enzyme. *Biochem. Soc. Trans.* **33**, 747–753
597 (2005).
5985. Whitehouse, C. J. C., Bell, S. G. & Wong, L.-L. P450_{BM3} (CYP102A1): connecting the dots.
599 *Chem. Soc. Rev.* **41**, 1218–1260 (2012).
6006. Bernhardt, R. & Urlacher, V. B. Cytochromes P450 as promising catalysts for
601 biotechnological application: Chances and limitations. *Appl. Microbiol. Biotechnol.* **98**,

- 602 6185–6203 (2014).
6037. Paddon, C. J. *et al.* High-level semi-synthetic production of the potent antimalarial
604 artemisinin. *Nature* **496**, 528–532 (2013).
6058. Kaluzna, I. *et al.* Enabling Selective and Sustainable P450 Oxygenation Technology.
606 Production of 4-Hydroxy- α -isophorone on Kilogram Scale. *Org. Process Res. Dev.* **20**,
607 814–819 (2016).
6089. Guzik, U. & Hupert-kocurek, K. Immobilization as a Strategy for Improving Enzyme
609 Properties-Application to Oxidoreductases. 8995–9018 (2014).
610 doi:10.3390/molecules19078995
61110. Tischer, W. & Wedekind, F. Immobilized Enzymes: Methods and Applications. *Biocatal.*
612 *Discov. to Appl.* **200**, 95–126 (1999).
61311. DiCosimo, R., McAuliffe, J., Poulose, A. J. & Bohlmann, G. Industrial use of immobilized
614 enzymes. *Chem. Soc. Rev.* **42**, 6437 (2013).
61512. Santos, J. C. S. D. *et al.* Importance of the Support Properties for Immobilization or
616 Purification of Enzymes. *ChemCatChem* **7**, 2413–2432 (2015).
61713. Maurer, S. C., Schulze, H., Schmid, R. D. & Urlacher, V. Immobilisation of P450BM-3 and
618 an NADP(+) cofactor recycling system: Towards a technical application of heme-
619 containing monooxygenases in fine chemical synthesis. *Adv. Synth. Catal.* **345**, 802–810
620 (2003).
62114. Axarli, I., Prigipaki, A. & Labrou, N. E. Engineering the substrate specificity of
622 cytochrome P450 CYP102A2 by directed evolution : production of an efficient enzyme
623 for bioconversion of fine chemicals. **22**, 81–88 (2005).
62415. Weber, E. *et al.* Immobilization of P450 BM-3 monooxygenase on mesoporous

- 625 molecular sieves with different pore diameters. *J. Mol. Catal. B Enzym.* **64**, 29–37
 626 (2010).
62716. Zhao, L., Güven, G., Li, Y. & Schwaneberg, U. First steps towards a Zn/Co(III)sep-driven
 628 P450 BM3 reactor. *Appl. Microbiol. Biotechnol.* **91**, 989–999 (2011).
62917. Lee, J. H. *et al.* New platform for cytochrome P450 reaction combining in situ
 630 immobilization on biopolymer. *Bioconjug. Chem.* **25**, 2101–2104 (2014).
63118. Zernia, S. *et al.* Peptide-Mediated Specific Immobilization of Catalytically Active
 632 Cytochrome P450 BM3 Variant. *Bioconjug. Chem.* **27**, 1090–7 (2016).
63319. Tan, C. Y., Hirakawa, H., Suzuki, R., Haga, T. & Iwata, F. Immobilization of a Bacterial
 634 Cytochrome P450 Monooxygenase System on a Solid Support. 1–6 (2016).
 635 doi:10.1002/anie.201608033
63620. Ferrero, V. E. V *et al.* Protein and electrode engineering for the covalent immobilization
 637 of P450 BMP on gold. *Anal. Chem.* **80**, 8438–8446 (2008).
63821. Neeli, R., Roitel, O., Scrutton, N. S. & Munro, A. W. Switching pyridine nucleotide
 639 specificity in P450 BM3: Mechanistic analysis of the W1046H and W1046A enzymes. *J.*
 640 *Biol. Chem.* **280**, 17634–17644 (2005).
64122. Cirino, P. C. & Arnold, F. H. A self-sufficient peroxide-driven hydroxylation biocatalyst.
 642 *Angew. Chemie - Int. Ed.* **42**, 3299–3301 (2003).
64323. Vidal-Limón, A., Águila, S., Ayala, M., Batista, C. V. & Vazquez-Duhalt, R. Peroxidase
 644 activity stabilization of cytochrome P450BM3 by rational analysis of intramolecular
 645 electron transfer. *J. Inorg. Biochem.* **122**, 18–26 (2013).
64624. Sadeghi, S. J., Fantuzzi, A. & Gilardi, G. Breakthrough in P450 bioelectrochemistry and
 647 future perspectives. *Biochim. Biophys. Acta - Proteins Proteomics* **1814**, 237–248 (2011).

64825. Holtmann, D., Mangold, K. M. & Schrader, J. Entrapment of cytochrome P450 BM-3 in
649 polypyrrole for electrochemically- driven biocatalysis. *Biotechnol. Lett.* **31**, 765–770
650 (2009).
65126. Sugihara, N., Ogoma, Y., Abe, K., Kondo, Y. & Akaike, T. Immobilization of cytochrome P-
652 450 and electrochemical control of its activity. *Polym. Adv. Technol.* **9**, 307–313 (1998).
65327. Munge, B., Estavillo, C., Schenkman, J. B. & Rusling, J. F. Optimization of Electrochemical
654 and Peroxide-Driven Oxidation of Styrene with Ultrathin Polyion Films Containing
655 Cytochrome P450 cam and Myoglobin. **6032**, 82–89 (2003).
65628. Chenault, H. K., Simon, E. S. & Whitesides, G. M. Cofactor regeneration for enzyme-
657 catalysed synthesis. *Biotechnology and Genetic Engineering Reviews* **6**, 221–270 (1988).
65829. Hollmann, F., Hofstetter, K. & Schmid, A. Non-enzymatic regeneration of nicotinamide
659 and flavin cofactors for monooxygenase catalysis. *Trends Biotechnol.* **24**, 163–171
660 (2006).
66130. Liu, W. & Wang, P. Cofactor regeneration for sustainable enzymatic biosynthesis.
662 *Biotechnol. Adv.* **25**, 369–384 (2007).
66331. Lundemo, M. T. & Woodley, J. M. Guidelines for development and implementation of
664 biocatalytic P450 processes. *Appl. Microbiol. Biotechnol.* **99**, 2465–2483 (2015).
66532. Schewe, H., Kaup, B. A. & Schrader, J. Improvement of P450BM-3whole-cell biocatalysis
666 by integrating heterologous cofactor regeneration combining glucose facilitator and
667 dehydrogenase in *E. coli*. *Appl. Microbiol. Biotechnol.* **78**, 55–65 (2008).
66833. Beyer, N. *et al.* P450 BM3 fused to phosphite dehydrogenase allows phosphite-driven
669 selective oxidations. *Appl. Microbiol. Biotechnol.* (2016). doi:10.1007/s00253-016-7993-
670 7

67134. Lu, Y. & Mei, L. Co-expression of P450 BM3 and glucose dehydrogenase by recombinant
672 *Escherichia coli* and its application in an NADPH-dependent indigo production system. *J.*
673 *Ind. Microbiol. Biotechnol.* **34**, 247–253 (2007).
67435. Smith, L. D., Budgen, N., Bungard, S. J., Danson, M. J. & Hough, D. W. Purification and
675 characterization of glucose dehydrogenase from the thermoacidophilic
676 archaeobacterium *Thermoplasma acidophilum*. *Biochem. J.* **261**, 973–7 (1989).
67736. Munishwar, N. G. Methods for Affinity Based Separations of Enzymes and Proteins. 120
67837. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram
679 quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **72**,
680 248–254 (1976).
68138. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of
682 bacteriophage T4. *Nature* **227**, 680–685 (1970).
68339. Omura, Tsuneo; Sato, R. The Carbon Monoxide-binding pigment of Liver Microsomes. *J.*
684 *Biol. Chem.* **239**, 2370–2378 (1964).
68540. Guengerich, F. P., Martin, M. V, Sohl, C. D. & Cheng, Q. Measurement of cytochrome
686 P450 and NADPH – cytochrome P450 reductase. **4**, 1245–1252 (2009).
68741. Weckbecker, A. & Hummel, W. Glucose Dehydrogenase for the Regeneration of NADPH
688 and NADH. *Microb. Enzym. Biotransformations* **17**, 225–238 (2005).
68942. Srivastava, P. K. & Singh, S. Immobilization and Applications of Glucose-6-Phosphate
690 Dehydrogenase: a Review. *Prep. Biochem. Biotechnol.* **43**, 376–384 (2013).
69143. Munro, A. W. *et al.* P450 BM3 : the very model of a modern flavocytochrome. **27**, 250–
692 257 (2002).
69344. Álvaro, G., Fernández-Lafuente, R., Blanco, R. M. & Guisan, J. M. Immobilization-

694 Stabilization of Penicillin G Acylase from Escherichia Coli. 181–195 (1989).

69545. Katchalski-Katzir, E. & Kraemer, D. M. Eupergit® C, a carrier for immobilization of
696 enzymes of industrial potential. *J. Mol. Catal. - B Enzym.* **10**, 157–176 (2000).

69746. Mateo, C. *et al.* Glyoxyl agarose: A fully inert and hydrophilic support for immobilization
698 and high stabilization of proteins. *Enzyme Microb. Technol.* **39**, 274–280 (2006).

69947. Goheer, M. a, Gould, B. J. & Parke, D. V. Preparation of immobilized baker's-yeast
700 glucose 6-phosphate dehydrogenase attached to modified sepharose and sephadex and
701 a comparison of the properties of these preparations with those of the soluble enzyme.
702 *Biochem. J.* **157**, 289–294 (1976).

70348. Persson, M., Bülow, L. & Mosbach, K. Purification and site-specific immobilization of
704 genetically engineered glucose dehydrogenase on thiopropyl-sepharose. *FEBS Lett.* **270**,
705 41–44 (1990).

70649. Karuzina, I. I. & Archakov, A. I. The oxidative inactivation of cytochrome P450 in
707 monooxygenase reactions. *Free Radic. Biol. Med.* **16**, 73–97 (1994).

70850. Petrovič, T., Hegyi, Z., Smonou, I., Rosenberg, M. & Rebroš, M. Co-Immobilization of
709 Ketoreductase and Glucose Dehydrogenase. (2018). doi:10.3390/catal8040168

71051. Urlacher, V. B. & Girhard, M. Cytochrome P450 monooxygenases: perspectives for
711 synthetic application. *Trends Biotechnol.* **24**, 324–330 (2006).

712

713

714

715

716TABLES

Enzyme	[Protein] (mg protein/m L lysate)	Specific Activity (U/mg protein)	Enzyme* (mg enzyme/mg protein)	[Enzyme] (mg enzyme/mL lysate)	P450 BM3 active form concentration† (μM)
P450 BM3	45.4±0.8	2.8±0.6	0.52±0.01	23.8±0.6	44.9±2.1
GDH		3.6±0.4	0.14±0.01	6.64±0.16	-

717**Table 1.** Characterization of the cell free extract containing P450 BM3 and Glucose

718dehydrogenase.

719

720*Data obtained from SDS-PAGE analysis

721†Data obtained from CO difference spectrum assay

723

724

725

726

727

728

729


730

731


Table 2. Main characteristics of the matrices tested and their results regarding immobilization and retained activity of P450 BM3. The criterion chosen to select a support for further studies sets a minimum for Immobilization at 90% and 25% for Retained activity.

Code	Functional group (Linker)	Matrix	Interaction	Pore diameter (Å)	Particle size (µm)	Immobilization Yield (%)	Retained activity (%)
ECR8204F	Epoxy	Methacrylate	Covalent	300-600	150-300	92±4	0
ECR8215F	Epoxy	Methacrylate	Covalent	1200-1800	150-300	99±1	2±1
ECR8309F	Amino (C2)	Methacrylate	Ionic/Covalent	600-1200	150-300	95±5	3±2
ECR8315F	Amino (C2)	Methacrylate	Ionic/Covalent	1200-1800	150-300	97±2	4±2
ECR8409F	Amino (C6)	Methacrylate	Ionic/Covalent	600-1200	150-300	100	6±3
ECR8415F	Amino (C6)	Methacrylate	Ionic/Covalent	1200-1800	150-300	98±1	18±1
ECR8285	Epoxy (C4)	Methacrylate	Ionic/Covalent	400-600	300-710	100	3±2
ECR8806F	None (C18)	Methacrylate	Hydrophobic	500-700	150-300	93±2	0
ECR1061M	None	Styrene/Methacrylic	Hydrophobic	600-750	300-710	21±6	0
ECR1030M	None	Styrene/Methacrylic	Hydrophobic	200-300	300-710	33±1	7±14
Praesto 45	Epoxy	Agarose	Covalent	ND	45	92±6	63±1
Praesto 65	Epoxy	Agarose	Covalent	ND	65	95±1	68±3
Praesto 90	Epoxy	Agarose	Covalent	ND	90	95±1	60±11

734 **FIGURES**



735
736 **Figure 1.** Scheme of the bi-functional self-sufficient oxidative biocatalyst obtained by the co-
737 immobilization of P450 BM3 from *Bacillus megaterium* and a GDH from *Thermoplasma*
738 *acidophilum* as cofactor-regenerating enzyme.




751

752**Figure 2.** SDS-PAGE gel containing a lysate co-expressing P450 BM3 and GDH (left lane) and a
 753molecular weight standard Bio-Rad Precision Plus (right lane). Numbers on both sides
 754represent the molecular weight of the protein bands (kDa).

755

756


757



758

Figure 3. P450 BM3 immobilization onto: A) Praesto 45 [discontinued line (-----)], 65 [dotted line (.....)] and 90 [combined dotted and discontinued line (-----)] [Sodium Phosphate Buffer 1 M pH 8] B) Epoxy-agarose-Sigma [Sodium Phosphate Buffer 1 M pH 8]; (I) the enzyme is bound to the support (II) β -mercaptoethanol 0.2 M final concentration is added to eliminate the unreacted epoxy groups, C) Epoxy-agarose-UAB [Sodium Phosphate Buffer 1 M pH 8] and D) AMINO-agarose [Sodium phosphate buffer 0.05 M pH 6]; (I) adsorption of the enzyme to the support (II) incubation with certain amount of carbodiimide (EDC) (III) incubation with 0.5 M NaCl and desorption of the unattached protein. The activity offered always ranged from 3.5 to 76 U/g of resin. The activities of a blank (squares), the supernatant (rhombus) and the suspension (triangle) were continuously analysed. Error bars correspond to standard deviation (n=2).

770



771

772**Figure 4.** Optimization of the EDC concentration in AMINO-agarose experiments using high
 773loads. The immobilization was carried out using sodium phosphate buffer 50 mM pH 6 and
 774offering 92 U/g of resin. Retained activity (black dots) and immobilization yield (grey bars) are
 775represented. Error bars correspond to standard deviation (n=2).

776

777

778

779

780

781

782

783


784

785

786

71

72



787

Figure 5. Reaction cycles using both P450 BM3 and GDH immobilized onto: A) Epoxy-agarose-789UAB (10 mg of agarose/mL), B) AMINO-agarose (10 mg of agarose/mL) and C) Lentikats® (50790mg of Lentikats/mL). Reactions were carried on in 5 mL scale adding 0.18-0.2 U of total activity

791and using sodium phosphate buffer 50 mM pH 7.5, 1.3 mM sodium laurate, 0.2 mM NADP⁺,
79212.5 mM D-glucose, temperature control at 25°C and constant 1000rpm agitation using a
793Multi-Therm H5000-HC-E thermos shaker. Error bars correspond to standard deviation (n=2)